Journal article

. Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.


Research Areas

Currently no objects available


Publication Details

Author list: Kaelo K. Seatlaa,b,f, Ava Avalosd,f,h, Sikhulile Moyoa,e,
Madisa Minea,d, Thabo Diphokoa,b,
Mosepele Mosepelea,c,f, Tendani Gaolatlhea,c,
Christopher F. Rowleye
, Dinah Ramaabyad
,
Joseph N. Jarvisa,c,f,g, Ishmael Kasvosveb
and Simani Gaseitsiwea,

Publication year: 2018

Volume number: 32

Issue number: 12



There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.


Projects

Currently no objects available


Keywords

Currently no objects available


Documents

Currently no objects available


Last updated on 2026-03-02 at 15:45